精囊蛋白SG1在肾透明细胞癌中的表达和预后意义

目的探讨精囊蛋白SG1在肾透明细胞癌患者癌旁组织和癌组织中的表达差异,结合临床指标,研究其临床意义。方法以qRT-PCR检测24例明确诊断为肾透明细胞癌患者的癌组织和癌旁组织中的SG1表达水平,以免疫组化研究53例肾透明细胞癌标本中的SG1蛋白表达水平,并进一步研究其临床意义。结果 qRT-PCR显示癌组织中的SG1水平明显低于癌旁组织的(P<0.01)。53例癌组织中,抗SG1免疫组化染色30例阳性(57%),明显低于对应癌旁组织的全部阳性(100%)。SG1表达量和肾透明细胞癌临床分期呈负相关(pT1² vs.pT32 vs.pT3⁴,P<0.000 1),且SG1表达阴性的患者复发概率升高(P<0.01)。结论 SG1在肾透明细胞癌中为低表达,SG1可预测肾透明细胞癌的进展和预后。

Seminal plasma protein in clear cell renal cell carcinoma:expression of Semenogelin I is a predictor for cancer progression and prognosis

Objective The incidence of clear renal cell carcinoma（ccRCC） has been steadily rising each year. There are currently few recognized biomarkers for the diagnosis and prognosis of ccRCC. We investigated Semonogelin I （SG1）expression and. its clinical significance in patients with ccRCC, Methods The expression level of SG1 was measured by qRT-PCR. Immunohistochemis~ry was used to invest/g#to the protein expression of SG1 in ccRCC and normal renal tissue from 53 patients. The Kaplan-Meier method and log-rank test were used to evaluate the data. Results By qRT-RCR （P〈0.01）, the level of SG1 expression in benign tissues was higher than that in ccRCC tissues. Expression of SG1 was observed in 30 （57%） ccRCC, which was signficantly lower than thai observed in benign renal tissues from the same patients SG1-positive in 53 （100%） cases （p〈0.01）] by immunohistochemistry. There was an inverse relation between SG1 expression and clinical stage （pT1-2 vs. pT3-4, P〈0.000 1）. Patients with SG1-negative tumors had a significantly higher risk of recurrence （Kaplan-Meier and Log-rank tests, P〈0.01）. Conclusion There is low SG1 expression in ccRCC. SG1 expression has potential value in predicting cancer progression and prognosis. These findings support the use of SG1 as a novel biomarker for ccRCC.